

# Peter A Vandenberghe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9440588/publications.pdf>

Version: 2024-02-01

280  
papers

19,695  
citations

16791

66  
h-index

13274

135  
g-index

288  
all docs

288  
docs citations

288  
times ranked

21839  
citing authors

#	ARTICLE	IF	CITATIONS
1	Overactive WASp in X-linked neutropenia leads to aberrant B-cell division and accelerated plasma cell generation. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1069-1084.	1.5	5
2	COVID-19 Vaccination Safety and Tolerability in Patients Allegedly at High Risk for Immediate Hypersensitivity Reactions. <i>Vaccines</i> , 2022, 10, 286.	2.1	8
3	Combined lenalidomide/bortezomib for multiple myeloma complicated by fulminant myocarditis: a rare case report of widely used chemotherapy. <i>European Heart Journal - Case Reports</i> , 2022, 6, ytac093.	0.3	4
4	Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 243-250.	1.0	4
5	Pan-Cancer Detection and Typing by Mining Patterns in Large Genome-Wide Cell-Free DNA Sequencing Datasets. <i>Clinical Chemistry</i> , 2022, 68, 1164-1176.	1.5	6
6	Ultra-low coverage whole genome sequencing of ccfDNA in multiple myeloma: A tool for laboratory routine?. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100380.	0.7	3
7	Constitutive activation of WASp leads to abnormal cytotoxic cells with increased granzyme B and degranulation response to target cells. <i>JCI Insight</i> , 2021, 6, .	2.3	7
8	BIRD-2, a BH4-domain-targeting peptide of Bcl-2, provokes Bax/Bak-independent cell death in B-cell cancers through mitochondrial Ca <sup>2+</sup> -dependent mPTP opening. <i>Cell Calcium</i> , 2021, 94, 102333.	1.1	28
9	14q32 rearrangements deregulating <i>BCL11B</i> mark a distinct subgroup of T and myeloid immature acute leukemia. <i>Blood</i> , 2021, 138, 773-784.	0.6	19
10	Case Report: Spontaneous Remission of an Infraorbital Follicular B-Cell Lymphoma: Case Report and Review of the Literature. <i>Pathology and Oncology Research</i> , 2021, 27, 642433.	0.9	0
11	The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNA. <i>Blood Advances</i> , 2021, 5, 1991-2002.	2.5	15
12	Comprehensive genome-wide analysis of routine non-invasive test data allows cancer prediction: A single-center retrospective analysis of over 85,000 pregnancies. <i>EClinicalMedicine</i> , 2021, 35, 100856.	3.2	42
13	An Update of Safety and Efficacy Results from Phase 1 Dose-Escalation and Expansion Study of Vodobotinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI), in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing Prior TKI Therapies. <i>Blood</i> , 2021, 138, 309-309.	0.6	3
14	Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma. <i>Blood</i> , 2020, 135, 1685-1695.	0.6	28
15	Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. <i>Pharmaceutics</i> , 2020, 12, 194.	2.0	40
16	The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants. <i>Nature Communications</i> , 2020, 11, 1044.	5.8	81
17	Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. <i>OncolImmunology</i> , 2020, 9, 1703449.	2.1	156
18	Ultra-low depth sequencing of plasma cell ccfDNA for the detection of copy number aberrations in multiple myeloma. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 465-471.	1.5	3

#	ARTICLE	IF	CITATIONS
19	In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1751-1766.	2.0	36
20	FER and FES tyrosine kinase fusions in follicular T-cell lymphoma. <i>Blood</i> , 2020, 135, 584-588.	0.6	16
21	Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib. <i>Blood</i> , 2020, 136, 51-52.	0.6	20
22	Constitutive IP3 signaling underlies the sensitivity of B-cell cancers to the Bcl-2/IP3 receptor disruptor BIRD-2. <i>Cell Death and Differentiation</i> , 2019, 26, 531-547.	5.0	69
23	Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma. <i>Haematologica</i> , 2019, 104, e17-e20.	1.7	18
24	Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 689-697.	1.5	8
25	Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis. <i>Annals of Hematology</i> , 2019, 98, 1421-1426.	0.8	14
26	Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. <i>Leukemia</i> , 2019, 33, 1910-1922.	3.3	54
27	FIP1L1â€PDGFRÎ± p.T674Iâ€D842L: A Novel and Ponatinib Resistant Compound Mutation in FIP1L1â€PDGFRÎ± Positive Leukemia. <i>HemaSphere</i> , 2019, 3, e182.	1.2	1
28	Genomewide copy number alteration screening of circulating plasma DNA: potential for the detection of incipient tumors. <i>Annals of Oncology</i> , 2019, 30, 85-95.	0.6	35
29	A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. <i>Haematologica</i> , 2018, 103, 840-848.	1.7	45
30	Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project. <i>Annals of Oncology</i> , 2018, 29, 200-208.	0.6	25
31	Clinicopathological characteristics of de novo and secondary myeloid sarcoma: A monocentric retrospective study. <i>European Journal of Haematology</i> , 2018, 100, 603-612.	1.1	32
32	Other immunomodulatory agent-related lymphoproliferative diseases: a single-center series of 72 biopsy-confirmed cases. <i>Modern Pathology</i> , 2018, 31, 1457-1469.	2.9	6
33	EML1â€ABL1 Is Activated by Coiledâ€Coilâ€Mediated Oligomerization and Induces Tâ€Cell Acute Lymphoblastic Leukemia or Myeloproliferative Disease in a Mouse Bone Marrow Transplant Model. <i>HemaSphere</i> , 2018, 2, e32.	1.2	2
34	Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients. <i>Hematology</i> , 2018, 23, 785-792.	0.7	23
35	Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2018, 32, 1358-1369.	3.3	66
36	Improved survival after LTx-associated acute GVHD with mAb therapy targeting IL2Rab and soluble TNFAb: Single-center experience and systematic review. <i>American Journal of Transplantation</i> , 2018, 18, 3007-3020.	2.6	2

#	ARTICLE	IF	CITATIONS
37	<i>BCR-ABL1</i> positive B-ALL can undergo T-cell lineage shift to become CD19-negative T-ALL. <i>HemaSphere</i> , 2018, 2, e42.	1.2	2
38	Constitutive activation of WASp in X-linked neutropenia renders neutrophils hyperactive. <i>Journal of Clinical Investigation</i> , 2018, 128, 4115-4131.	3.9	35
39	Unraveling the Landscape of Copy Number Aberrations in Hodgkin Lymphoma: A Joint KU Leuven and Lysa Study on Circulating Cell Free DNA. <i>Blood</i> , 2018, 132, 2836-2836.	0.6	0
40	Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing. <i>Blood</i> , 2018, 132, 2861-2861.	0.6	0
41	Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 2838-2838.	0.6	1
42	Highly sensitive assays are mandatory for the differential diagnosis of patients presenting with symptoms of mast cell activation: diagnostic work-up of 38 patients. <i>Acta Clinica Belgica</i> , 2017, 72, 123-129.	0.5	2
43	Multipotent adult progenitor cells improve the hematopoietic function in myelodysplasia. <i>Cytotherapy</i> , 2017, 19, 744-755.	0.3	3
44	RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response. <i>Leukemia</i> , 2017, 31, 1706-1714.	3.3	49
45	An incidental finding of maternal multiple myeloma by non invasive prenatal testing. <i>Prenatal Diagnosis</i> , 2017, 37, 1257-1260.	1.1	13
46	Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene. <i>Haematologica</i> , 2017, 102, 1605-1616.	1.7	29
47	Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 2289-2300.	3.2	38
48	Genomic alterations of the <i>JAK2</i> and <i>PDL</i> loci occur in a broad spectrum of lymphoid malignancies. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 428-441.	1.5	41
49	EBV-Positive and EBV-Negative Posttransplant Diffuse Large B Cell Lymphomas Have Distinct Genomic and Transcriptomic Features. <i>American Journal of Transplantation</i> , 2016, 16, 414-425.	2.6	70
50	Secondary B-cell lymphoma associated with the Epstein-Barr virus in chronic lymphocytic leukemia patients. <i>Journal of Hematopathology</i> , 2016, 9, 113-120.	0.2	10
51	The role of the RAS pathway in iAMP21-ALL. <i>Leukemia</i> , 2016, 30, 1824-1831.	3.3	38
52	Circulating cell-free DNA in hematological malignancies. <i>Haematologica</i> , 2016, 101, 997-999.	1.7	16
53	A Lysa Phase II Study of Oral JAK1/2 Inhibitor Ruxolitinib in Advanced Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL). <i>Blood</i> , 2016, 128, 4160-4160.	0.6	2
54	IGH-Mediated Translocations, Recurrent in Classic Hodgkin Lymphoma, Frequently Correlate with an Aggressive Behavior. <i>Blood</i> , 2016, 128, 2922-2922.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern. <i>Haematologica</i> , 2015, 100, e275-e279.	1.7	76
56	The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 13-21.	0.6	168
57	Hedgehog pathway mutations in T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, e102-e105.	1.7	35
58	Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations. <i>Haematologica</i> , 2015, 100, 893-897.	1.7	49
59	t(15;21) translocations leading to the concurrent downregulation of RUNX1 and its transcription factor partner genes SIN3A and TCF12 in myeloid disorders. <i>Molecular Cancer</i> , 2015, 14, 211.	7.9	12
60	Validation of a locked nucleic acid based wild-type blocking PCR for the detection of EGFR exon 18/19 mutations. <i>Diagnostic Pathology</i> , 2015, 10, 57.	0.9	6
61	Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing. <i>JAMA Oncology</i> , 2015, 1, 814.	3.4	180
62	NUP98/11p15 translocations affect CD34+ cells in myeloid and T lymphoid leukemias. <i>Leukemia Research</i> , 2015, 39, 769-772.	0.4	12
63	Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study. <i>Lancet Haematology</i> , 2015, 2, e55-e65.	2.2	115
64	Clonal chromosomal abnormalities in Ph-negative cells in chronic myeloid leukemia: an unusual case evolving to secondary acute myeloid leukemia. <i>Cancer Genetics</i> , 2015, 208, 102-104.	0.2	1
65	TAF10 Interacts with the GATA1 Transcription Factor and Controls Mouse Erythropoiesis. <i>Molecular and Cellular Biology</i> , 2015, 35, 2103-2118.	1.1	14
66	Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene. <i>Annals of Hematology</i> , 2015, 94, 1927-1928.	0.8	51
67	Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, 1301-1310.	1.7	151
68	Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells. <i>Leukemia</i> , 2015, 29, 1092-1103.	3.3	161
69	RPL5 Is a Candidate Tumor Suppressor on 1p22.1 in Multiple Myeloma of Which the Expression Is Linked to Bortezomib Response. <i>Blood</i> , 2015, 126, 2969-2969.	0.6	0
70	Identification of Candidate Oncogenes and Chromosomal Breakpoint Sequencing By Targeted Locus Amplification in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 1409-1409.	0.6	0
71	ALK-Positive Anaplastic Large Cell Lymphoma with the Variant EEF1G-, RNF213- and Atic-ALK Fusions Is Featured By Copy Number Gain of the Rearranged ALK Gene. <i>Blood</i> , 2015, 126, 3654-3654.	0.6	0
72	MPL p.S204P Is a Recurrent Mutation in Essential Thrombocythemia. <i>Blood</i> , 2015, 126, 2837-2837.	0.6	1

#	ARTICLE	IF	CITATIONS
73	BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia. <i>Blood</i> , 2015, 126, 1569-1569.	0.6	0
74	Non-IG Aberrations of FOXP1 in B-Cell Malignancies Lead to an Aberrant Expression of N-Truncated Isoforms of FOXP1. <i>PLoS ONE</i> , 2014, 9, e85851.	1.1	18
75	Integrative Genomic and Transcriptomic Analysis Identified Candidate Genes Implicated in the Pathogenesis of Hepatosplenic T-Cell Lymphoma. <i>PLoS ONE</i> , 2014, 9, e102977.	1.1	48
76	Translocation t(1;11)(q21;q23): a new finding in congenital acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 1435-1436.	0.6	2
77	Identification of a novel, recurrent <i>MBTD1</i> – <i>Xorf67</i> fusion in low-grade endometrial stromal sarcoma. <i>International Journal of Cancer</i> , 2014, 134, 1112-1122.	2.3	117
78	Screening of <i>JAK2</i> V617F and <i>MPL</i> W515 K/L negative essential thrombocythaemia patients for mutations in <i>SESN2</i> , <i>DNAJC17</i> , <i>ST13</i> , <i>TOP1</i> , <i>MT</i> , and <i>NTRK1</i> . <i>British Journal of Haematology</i> , 2014, 165, 734-737.	1.2	5
79	Suitability of Small Bronchoscopic Tumour Specimens for Lung Cancer Genotyping. <i>Respiration</i> , 2014, 88, 371-377.	1.2	10
80	A case with a cytogenetically cryptic variant of the inv(16)(p13q22)/t(16;16)(p13;q22). <i>Cancer Genetics</i> , 2014, 207, 231-232.	0.2	4
81	Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. <i>Nature</i> , 2014, 508, 98-102.	13.7	261
82	An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. <i>Leukemia</i> , 2014, 28, 1015-1021.	3.3	175
83	Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib. <i>Annals of Hematology</i> , 2014, 93, 2087-2089.	0.8	26
84	Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFR $\alpha$ . <i>Experimental Hematology</i> , 2014, 42, 282-293.e4.	0.2	41
85	Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. <i>Blood</i> , 2014, 123, 2229-2237.	0.6	135
86	In Vitro Characterization of Peripheral Blood Progenitor Cell Differentiation and Platelet Function in Essential Thrombocythemia (ET). <i>Blood</i> , 2014, 124, 1877-1877.	0.6	0
87	Analysis of Genotype, Phenotype and Outcome in a Belgian Cohort of Essential Thrombocythemia. <i>Blood</i> , 2014, 124, 5584-5584.	0.6	0
88	TAF10 Interacts with GATA1 Transcription Factor and Controls Mouse Erythropoiesis. <i>Blood</i> , 2014, 124, 2912-2912.	0.6	0
89	BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant. <i>Blood</i> , 2014, 124, 4512-4512.	0.6	1
90	Chromosomal translocations involving the IGH@ locus in B-cell precursor acute lymphoblastic leukemia: 29 new cases and a review of the literature. <i>Cancer Genetics</i> , 2013, 206, 162-173.	0.2	29

#	ARTICLE	IF	CITATIONS
91	Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2013, 45, 186-190.	9.4	365
92	Deregulated Expression of <i>EVI1</i> Defines a Poor Prognostic Subset of <i>MLL</i> -Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. <i>Journal of Clinical Oncology</i> , 2013, 31, 95-103.	0.8	95
93	Patients with myelodysplastic syndrome and two clones with different interstitial deletions of the long arm of chromosome 5. <i>Leukemia and Lymphoma</i> , 2013, 54, 2314-2317.	0.6	0
94	Comprehensive Analysis of Transcriptome Variation Uncovers Known and Novel Driver Events in T-Cell Acute Lymphoblastic Leukemia. <i>PLoS Genetics</i> , 2013, 9, e1003997.	1.5	110
95	<i>BMI1</i> , The polycomb group gene, is recurrently targeted by genomic rearrangements in progressive B-cell leukemia/lymphoma. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 928-944.	1.5	20
96	Activation of the mTOR signaling pathway by L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts. <i>Leukemia</i> , 2013, 27, 1760-1763.	3.3	10
97	Cooperativity Of RUNX1 and CSF3R Mutations In The Development Of Leukemia In Severe Congenital Neutropenia: A Unique Pathway In Myeloid Leukemogenesis. <i>Blood</i> , 2013, 122, 444-444.	0.6	1
98	The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories. <i>Blood</i> , 2013, 122, 743-743.	0.6	6
99	JAK2 V617F-Negative and MPL W515K/L-Negative Essential Thrombocythemia: A High Resolution SNP Array Study. <i>Blood</i> , 2013, 122, 5258-5258.	0.6	0
100	Screening JAK2 V617F-Negative and MPL W515K/L-Negative Essential Thrombocythemia Patients For Mutations In SESN2, DNAJC17, ST13, TOP1MT, and NTRK1. <i>Blood</i> , 2013, 122, 5264-5264.	0.6	0
101	Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing. <i>Blood</i> , 2013, 122, 740-740.	0.6	0
102	Axl Represents a Therapeutic Target In T315I-Mutated and WT Chronic Myeloid Leukemia. <i>Blood</i> , 2013, 122, 1469-1469.	0.6	0
103	Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFR $\alpha$ and KIT, and against FGFR1-derived fusion kinases. <i>Leukemia</i> , 2012, 26, 1693-1695.	3.3	63
104	t(X;14)(p11.4;q32.33) is recurrent in marginal zone lymphoma and up-regulates GPR34. <i>Haematologica</i> , 2012, 97, 184-188.	1.7	39
105	The different faces of Janus kinase inhibition. <i>Haematologica</i> , 2012, 97, 475-475.	1.7	0
106	Rearrangement of NOTCH1 or BCL3 can independently trigger progression of CLL. <i>Blood</i> , 2012, 119, 3864-3866.	0.6	12
107	Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia. <i>Blood</i> , 2012, 120, 1529-1531.	0.6	63
108	Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 607-612.e9.	1.5	604



#	ARTICLE	IF	CITATIONS
109	ICON: Eosinophil Disorders. World Allergy Organization Journal, 2012, 5, 174-181.	1.6	25
110	Recurrent breakpoints in 14q32.13/TCL1A region in mature B-cell neoplasms with villous lymphocytes. Leukemia and Lymphoma, 2012, 53, 2449-2455.	0.6	3
111	Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Review of Hematology, 2012, 5, 157-176.	1.0	140
112	Targeted Therapy with Rituximab in Felty's Syndrome: A Case Report. Open Rheumatology Journal, 2012, 6, 312-314.	0.1	6
113	Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia. Blood, 2012, 119, 4476-4479.	0.6	96
114	Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course. Annals of Hematology, 2012, 91, 863-873.	0.8	65
115	PDS5A, a novel translocation partner of MLL in acute myeloid leukemia. Leukemia Research, 2012, 36, e87-e89.	0.4	5
116	Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia?. Leukemia Research, 2012, 36, 832-840.	0.4	21
117	High Accuracy Mutation Detection in Leukemia on a Selected Panel of Cancer Genes. PLoS ONE, 2012, 7, e38463.	1.1	58
118	Translocation t(1;6)(p35.3;p25.2) Involves RCC1 and IRF4 and Is Not Restricted to Unmutated Chronic Lymphocytic Leukemia. Blood, 2012, 120, 4584-4584.	0.6	0
119	Non-IG Aberrations of FOXP1 in B-Cell Malignancies Result in an Aberrant Expression of N-Truncated FOXP1 Isoforms.. Blood, 2012, 120, 2411-2411.	0.6	0
120	Effects of Ponatinib and Other Novel TKI On Growth, Survival, and Function of Neoplastic Eosinophils Carrying FIP1L1/Pdgfra. Blood, 2012, 120, 1760-1760.	0.6	0
121	A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nature Genetics, 2011, 43, 673-678.	9.4	244
122	FOXP1 and PAX5 are rare but recurrent translocations partners in acute lymphoblastic leukemia. Cancer Genetics, 2011, 204, 462-464.	0.2	9
123	Amplification of the G allele at SNP rs6983267 in 8q24 amplicons in myeloid malignancies as cause of the lack of MYC overexpression?. Blood Cells, Molecules, and Diseases, 2011, 47, 259-261.	0.6	5
124	JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma. Blood, 2011, 117, 4056-4064.	0.6	103
125	Smad4 binds Hoxa9 in the cytoplasm and protects primitive hematopoietic cells against nuclear activation by Hoxa9 and leukemia transformation. Blood, 2011, 117, 5918-5930.	0.6	29
126	EV1 mediated down regulation of MIR449A is essential for the survival of EV1 positive leukaemic cells. British Journal of Haematology, 2011, 154, 337-348.	1.2	20



#	ARTICLE	IF	CITATIONS
127	PHF6 mutations in adult acute myeloid leukemia. <i>Leukemia</i> , 2011, 25, 130-134.	3.3	142
128	Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia. <i>Cancer Cell</i> , 2011, 19, 740-753.	7.7	124
129	PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2011, 117, 7090-7098.	0.6	76
130	CML with e6a2 BCR-ABL1 transcript: an aggressive entity?. <i>Annals of Hematology</i> , 2011, 90, 1241-1243.	0.8	10
131	The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories. <i>Leukemia</i> , 2011, 25, 1840-1848.	3.3	96
132	External Quality Assessment for <i>KRAS</i> Testing Is Needed: Setup of a European Program and Report of the First Joined Regional Quality Assessment Rounds. <i>Oncologist</i> , 2011, 16, 467-478.	1.9	83
133	The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11). <i>Haematologica</i> , 2011, 96, 922-926.	1.7	59
134	Severe congenital neutropenia, a genetically heterogeneous disease group with an increased risk of AML/MDS. <i>Mental illness</i> , 2011, 3, e9.	0.8	25
135	UPDATE On the RISK of SECONDARY LEUKEMIA In GENETIC SUBGROUPS (ELANE, HAX1, WAS, G6PC3, p14) of CONGENITAL NEUTROPENIA In EUROPE. <i>Blood</i> , 2011, 118, 1106-1106.	0.6	3
136	International Standardization of Minimal Residual Disease Assessment for in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) Expressing m-BCR-ABL Transcripts: Updated Results of Quality Control Procedures by the EWALL and ESG-MRD-ALL Consortia. <i>Blood</i> , 2011, 118, 2535-2535.	0.6	4
137	Ponatinib Is Active Against the CUX1-FGFR1 Fusion Kinase and Against Imatinib Resistance Mutations of the FIP1L1-PDGFR± Fusion Kinase and of KIT. <i>Blood</i> , 2011, 118, 3848-3848.	0.6	0
138	T(X;14)(p11.4;q32.33) Is Recurrent In Marginal Zone Lymphoma and Upregulates GPR34. <i>Blood</i> , 2011, 118, 1349-1349.	0.6	0
139	JAK2, As Well As PDL1 and PDL2, are Recurrently Targeted by 9p24 Structural and Numerical Aberrations in Lymphoid Neoplasms of Both B- and T-Cell Origin. <i>Blood</i> , 2011, 118, 2460-2460.	0.6	0
140	ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. <i>Haematologica</i> , 2010, 95, 509-513.	1.7	89
141	Interphase fluorescence in situ hybridization on selected plasma cells is superior in the detection of cytogenetic aberrations in plasma cell dyscrasia. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 991-997.	1.5	11
142	The t(14;20)(q32;q12): a rare cytogenetic change in multiple myeloma associated with poor outcome. <i>British Journal of Haematology</i> , 2010, 149, 901-904.	1.2	9
143	Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2010, 42, 530-535.	9.4	162
144	Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. <i>Nature Genetics</i> , 2010, 42, 665-667.	9.4	708

#	ARTICLE	IF	CITATIONS
145	Coactivated Platelet-Derived Growth Factor Receptor $\hat{\pm}$ and Epidermal Growth Factor Receptor Are Potential Therapeutic Targets in Intimal Sarcoma. <i>Cancer Research</i> , 2010, 70, 7304-7314.	0.4	80
146	Activating WASP mutations associated with X-linked neutropenia result in enhanced actin polymerization, altered cytoskeletal responses, and genomic instability in lymphocytes. <i>Journal of Experimental Medicine</i> , 2010, 207, 1145-1152.	4.2	67
147	Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 3890-3898.	0.8	217
148	The Kinase Inhibitor TKI258 Is Active Against the Novel CUX1-FGFR1 Fusion Detected In a Patient with T-Lymphoblastic Leukemia/Lymphoma and t(7;8)(q22;p11). <i>Blood</i> , 2010, 116, 2715-2715.	0.6	1
149	Results of An International Study of Quantitative BCR/ABL Assays Using Defined RNA Samples. <i>Blood</i> , 2010, 116, 2742-2742.	0.6	7
150	SMAD4 Sequesters HOXA9 to Protect Hematopoietic Stem Cells Against Leukemia Transformation. <i>Blood</i> , 2010, 116, 3153-3153.	0.6	3
151	Activating WASP mutations associated with X-linked neutropenia result in enhanced actin polymerization, altered cytoskeletal responses, and genomic instability in lymphocytes. <i>Journal of Cell Biology</i> , 2010, 189, i13-i13.	2.3	0
152	The Interlaboratory RObustness of Next-Generation Sequencing (IRON) Study: Deep-Sequencing Investigating TET2, CBL, and KRAS Mutations In 4464 Amplicons by An International Group Involving 8 Laboratories.. <i>Blood</i> , 2010, 116, 1665-1665.	0.6	0
153	Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Results of a Survey and First Control Round within 28 National Reference Laboratories In Europe. <i>Blood</i> , 2010, 116, 894-894.	0.6	1
154	G-CSF receptor (CSF3R) mutations in X-linked neutropenia evolving to acute myeloid leukemia or myelodysplasia. <i>Haematologica</i> , 2009, 94, 1449-1452.	1.7	36
155	Methylation analysis of the imprintedDLK1-GTL2domain supports the random parental origin of theIGH-involving del(14q) in B-cell malignancies. <i>Epigenetics</i> , 2009, 4, 469-475.	1.3	5
156	Recipient-derived chronic lymphocytic leukaemia diagnosed shortly after kidney transplantation on protocol biopsy. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3886-3890.	0.4	6
157	Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin $\hat{\epsilon}$ 2 stimulation: A Belgian multicentric study. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 843-853.	1.5	54
158	Hepatosplenic $\hat{\beta}$ T-cell lymphoma after liver transplantation: Report of the first 2 cases and review of the literature. <i>Liver Transplantation</i> , 2009, 15, 686-692.	1.3	23
159	P052 Acquired mutations in TET2 are common in myelodysplastic syndromes. <i>Leukemia Research</i> , 2009, 33, S88-S89.	0.4	3
160	Neonatal acute myeloid leukemia in an infant whose mother was exposed to diethylstilboestrol in utero. <i>Pediatric Blood and Cancer</i> , 2009, 53, 220-222.	0.8	12
161	A large kindred with X $\hat{\epsilon}$ linked neutropenia with an I294T mutation of the Wiskott $\hat{\epsilon}$ Aldrich syndrome gene. <i>British Journal of Haematology</i> , 2009, 144, 120-126.	1.2	90
162	Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2009, 23, 125-133.	3.3	65

#	ARTICLE	IF	CITATIONS
163	FIP1L1-PDGFR $\hat{I}$ ± D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFR $\hat{I}$ ± T6741 eosinophilic leukemia with single agent sorafenib. <i>Leukemia</i> , 2009, 23, 845-851.	3.3	123
164	Translocation t(14;18) is not associated with inferior outcome in chronic lymphocytic leukemia. <i>Leukemia</i> , 2009, 23, 1201-1204.	3.3	35
165	Acquired mutations in TET2 are common in myelodysplastic syndromes. <i>Nature Genetics</i> , 2009, 41, 838-842.	9.4	680
166	Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy. <i>Leukemia Research</i> , 2009, 33, 1703-1705.	0.4	4
167	The fusion proteins TEL-PDGFR $\hat{A}$ and FIP1L1-PDGFR $\hat{A}$ escape ubiquitination and degradation. <i>Haematologica</i> , 2009, 94, 1085-1093.	1.7	43
168	New flow cytometry in hematologic malignancies. <i>Haematologica</i> , 2009, 94, 1639-1641.	1.7	3
169	JAK2 Rearrangements, Including the Novel SEC31A-JAK2 Fusion, Are Recurrent in Classical Hodgkin Lymphoma.. <i>Blood</i> , 2009, 114, 140-140.	0.6	7
170	Update On the Risk of Leukemia in Genetic Subgroups of Congenital Neutropenia (CN): Comparison of Patients with Known Gene Mutations (ELA2, HAX1, WASP, G6PC3, p14).. <i>Blood</i> , 2009, 114, 3597-3597.	0.6	1
171	Deletion of the Protein Tyrosine Phosphatase Gene PTPN2 in T-Cell Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2009, 114, 141-141.	0.6	0
172	Placental Growth Factor: a Novel, Stromal-Derived Target in Human CML.. <i>Blood</i> , 2009, 114, 42-42.	0.6	0
173	BMI1, the Polycomb-Group Gene, Is Recurrently Targeted by Genomic Rearrangements in Progressive B-Cell Leukemia/Lymphoma.. <i>Blood</i> , 2009, 114, 1099-1099.	0.6	13
174	Downregulation of MiR-449a Is Essential for the Survival of EVI1 Positive Leukemic Cells through Modulation of NOTCH1 and BCL2.. <i>Blood</i> , 2009, 114, 361-361.	0.6	0
175	The clinical significance of activated lymphocytes in patients with myelodysplastic syndromes: A single centre study of 131 patients. <i>Leukemia Research</i> , 2008, 32, 1026-1035.	0.4	29
176	Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. <i>Blood</i> , 2008, 111, 5683-5690.	0.6	116
177	Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor $\hat{A}$ Associated PDGFRAD842V Mutation. <i>Clinical Cancer Research</i> , 2008, 14, 5749-5758.	3.2	116
178	Positron emission tomography in mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 1693-1701.	0.6	55
179	EVI1 overexpression in t(3;17) positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22. <i>Haematologica</i> , 2008, 93, 1903-1907.	1.7	29
180	In vitro validation of $\hat{A}$ -secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2008, 93, 533-542.	1.7	77

#	ARTICLE	IF	CITATIONS
181	t(3;11)(q12;p15)/NUP98-LOC348801 fusion transcript in acute myeloid leukemia. <i>Haematologica</i> , 2008, 93, 1398-1401.	1.7	22
182	High-Dose Therapy in AL Amyloidosis: A Prospective Phase II Study by the Dutch-Belgian Cooperative Group (HOVON). <i>Blood</i> , 2008, 112, 163-163.	0.6	2
183	The T(14;20)(q32;q12) : A Rare Cytogenetic Change in Multiple Myeloma Associated with Poor Outcome. <i>Blood</i> , 2008, 112, 2718-2718.	0.6	0
184	A Myelodysplastic Syndrome Associated with a Clonal GATA1 Mutation.. <i>Blood</i> , 2008, 112, 1243-1243.	0.6	0
185	MicroRNA signatures in Genetic Subtypes of T-Cell Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2008, 112, 3360-3360.	0.6	1
186	Improved Detection of Chromosomal Abnormalities in CLL by Conventional Cytogenetics Using CpG Oligonucleotide and Interleukin-2 Stimulation. A Belgian Multicentric Study. <i>Blood</i> , 2008, 112, 3118-3118.	0.6	0
187	Telomeric IGH Losses Detectable by Fluorescence in Situ Hybridization in Chronic Lymphocytic Leukemia Reflect Somatic VH Recombination Events. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 47-54.	1.2	37
188	Hodgkin lymphoma: Response assessment by Revised International Workshop Criteria. <i>Leukemia and Lymphoma</i> , 2007, 48, 1539-1547.	0.6	68
189	Aggressive and indolent non-Hodgkin's lymphoma: Response assessment by Integrated International Workshop Criteria. <i>Leukemia and Lymphoma</i> , 2007, 48, 1522-1530.	0.6	43
190	Is there a difference in childhood T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma?. <i>Leukemia and Lymphoma</i> , 2007, 48, 1745-1754.	0.6	46
191	Array CGH analysis in primary gastrointestinal stromal tumors: Cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 261-276.	1.5	106
192	Fusion gene-mediated truncation of RUNX1 as a potential mechanism underlying disease progression in the 8p11 myeloproliferative syndrome. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 635-643.	1.5	48
193	Immature and mature monocyte-derived dendritic cells in myelodysplastic syndromes of subtypes refractory anemia or refractory anemia with ringed sideroblasts display an altered cytokine profile. <i>Leukemia Research</i> , 2007, 31, 1373-1382.	0.4	33
194	Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2007, 39, 593-595.	9.4	252
195	FIP1L1-PDGFR $\alpha$ in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells. <i>Leukemia</i> , 2007, 21, 397-402.	3.3	21
196	A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification. <i>Leukemia</i> , 2007, 21, 668-677.	3.3	62
197	CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease. <i>Leukemia</i> , 2007, 21, 1451-1459.	3.3	50
198	Interstitial del(14)(q) involving IGH: a novel recurrent aberration in B-NHL. <i>Leukemia</i> , 2007, 21, 2079-2083.	3.3	39

#	ARTICLE	IF	CITATIONS
199	Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine. <i>Leukemia</i> , 2007, 21, 1715-1722.	3.3	83
200	Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosis. <i>Cancer Genetics and Cytogenetics</i> , 2007, 178, 11-16.	1.0	13
201	Multiple Myeloma with IGH-Involving del(14q): Report of 34 Cases.. <i>Blood</i> , 2007, 110, 991-991.	0.6	1
202	Identification of Novel Genetic Lesions in Myelodysplastic Syndromes Using High Density SNP-Arrays.. <i>Blood</i> , 2007, 110, 2430-2430.	0.6	0
203	Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. <i>Blood</i> , 2006, 107, 3053-3057.	0.6	390
204	Sorafenib is a potent inhibitor of FIP1L1-PDGFR $\hat{I}\pm$ and the imatinib-resistant FIP1L1-PDGFR $\hat{I}\pm$ T674I mutant. <i>Blood</i> , 2006, 108, 1374-1376.	0.6	128
205	Coexistence of light chain disease and chronic lymphocytic leukaemia, a complex karyotype with a rapid fatal outcome. <i>International Journal of Laboratory Hematology</i> , 2006, 28, 138-140.	0.2	0
206	CTLA-4 interacts with STAT5 and inhibits STAT5-mediated transcription. <i>Immunology</i> , 2006, 117, 396-401.	2.0	12
207	Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. <i>Leukemia</i> , 2006, 20, 1496-1510.	3.3	250
208	Transition from EML1-ABL1 to NUP214-ABL1 positivity in a patient with acute T-lymphoblastic leukemia. <i>Leukemia</i> , 2006, 20, 2202-2204.	3.3	10
209	Gain-of-Function WASP Mutations in Pediatric and Adult Patients with Myelodysplasia or AML.. <i>Blood</i> , 2006, 108, 4516-4516.	0.6	1
210	Genetics of t(11;14)(q13;q32)-Negative MCL.. <i>Blood</i> , 2006, 108, 2071-2071.	0.6	0
211	The CD40-Receptor Is Upregulated on Monocytes from Patients with Low-Risk Myelodysplastic Syndromes and Its Inhibition by a Monoclonal Anti-CD40 Antibody Can Increase Colony Formation.. <i>Blood</i> , 2006, 108, 2640-2640.	0.6	0
212	Involvement of the NOTCH1 and NOTCH2 Genes in B-Cell Lymphomagenesis.. <i>Blood</i> , 2006, 108, 2072-2072.	0.6	8
213	X-Linked Neutropenia with a I294T Mutation of the Wiskott-Aldrich Syndrome Gene.. <i>Blood</i> , 2006, 108, 1278-1278.	0.6	0
214	PAD Is a Highly Effective Regimen for the Treatment of Patients with Relapsed Refractory Multiple Myeloma.. <i>Blood</i> , 2006, 108, 5095-5095.	0.6	0
215	Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). <i>Blood</i> , 2005, 105, 4849-4852.	0.6	119
216	Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas. <i>Histopathology</i> , 2005, 46, 431-441.	1.6	50

#	ARTICLE	IF	CITATIONS
217	CD34+ marrow progenitors from MDS patients with high levels of intramedullary apoptosis have reduced expression of $\beta$ 4 $\beta$ 1 and $\beta$ 5 $\beta$ 1 integrins. <i>Leukemia</i> , 2005, 19, 57-63.	3.3	28
218	A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias. <i>Leukemia</i> , 2005, 19, 358-366.	3.3	106
219	Identification of e19a2 BCR $\beta$ -ABL fusions ( $\beta$ 4-BCR breakpoints) at the DNA level by ligation-mediated PCR. <i>Leukemia</i> , 2005, 19, 1292-1295.	3.3	11
220	FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. <i>Leukemia</i> , 2005, 19, 1299-1305.	3.3	141
221	Quantification of CFBF-MYH11 fusion gene levels in paired peripheral blood and bone marrow samples by real-time PCR. <i>Leukemia</i> , 2005, 19, 1988-1990.	3.3	13
222	Deletion of the inositide-specific phospholipase c $\beta$ 1 gene is a rare event in myelodysplastic syndrome and thus of limited value to predict leukemic progression. <i>Leukemia</i> , 2005, 19, 2011-2013.	3.3	5
223	Leukemic recombinations involving heterochromatin in myeloproliferative disorders with t(1;9). <i>Cancer Genetics and Cytogenetics</i> , 2005, 162, 45-49.	1.0	9
224	Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. <i>Cancer Cell</i> , 2005, 7, 387-397.	7.7	2,695
225	NOTCH1 Is Targeted by Ig Translocations in NHL.. <i>Blood</i> , 2005, 106, 4339-4339.	0.6	7
226	Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2004, 36, 1084-1089.	9.4	393
227	Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. <i>Leukemia</i> , 2004, 18, 734-742.	3.3	188
228	Circulating myeloid and lymphoid precursor dendritic cells are clonally involved in myelodysplastic syndromes. <i>Leukemia</i> , 2004, 18, 1451-1456.	3.3	57
229	A flow cytometric method for determination of absolute counts of myeloid precursor dendritic cells in peripheral blood. <i>Journal of Immunological Methods</i> , 2004, 285, 215-221.	0.6	17
230	A male with angioimmunoblastic T-cell lymphoma and proliferative glomerulonephritis. <i>Annals of Hematology</i> , 2004, 83, 455-459.	0.8	14
231	Case of megaloblastic anemia caused by intestinal taeniasis. <i>Annals of Hematology</i> , 2004, 83, 487-488.	0.8	27
232	FOXP1, a Highly Expressed Gene in a Subset of DLBCL, Is Targeted by a Recurrent t(3;14)(p13;q32).. <i>Blood</i> , 2004, 104, 2891-2891.	0.6	1
233	Fusion of NUP214 to ABL1 on Amplified Extrachromosomal Elements in T-ALL.. <i>Blood</i> , 2004, 104, 141-141.	0.6	3
234	Chromosomal Rearrangements Affecting ABL1 in T-Cell Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2004, 104, 2894-2894.	0.6	1



#	ARTICLE	IF	CITATIONS
235	Imatinib mesylate induces durable complete remission of advanced CML persisting after allogeneic bone marrow transplantation. <i>Leukemia</i> , 2003, 17, 458-460.	3.3	6
236	A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome. <i>New England Journal of Medicine</i> , 2003, 348, 1201-1214.	13.9	1,655
237	Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. <i>Blood</i> , 2003, 102, 53-59.	0.6	217
238	ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. <i>Blood</i> , 2003, 102, 2638-2641.	0.6	174
239	Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2002, 13, 1356-1363.	0.6	376
240	Comparative Genomic Hybridization Pattern Distinguishes T-Cell/Histiocyte-Rich B-Cell Lymphoma from Nodular Lymphocyte Predominance Hodgkin's Lymphoma. <i>American Journal of Pathology</i> , 2002, 161, 1861-1867.	1.9	67
241	Successful treatment with rituximab of lymphoproliferative disorder in a child after cardiac transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2002, 21, 1304-1309.	0.3	21
242	Blockade of CTLA-4 enhances allergic sensitization and eosinophilic airway inflammation in genetically predisposed mice. <i>European Journal of Immunology</i> , 2002, 32, 585-594.	1.6	81
243	Aplastic anemia after transplantation for non-A, non-B, non-C fulminant hepatic failure: case report and review of the literature. <i>Transplant International</i> , 2002, 15, 117-123.	0.8	13
244	Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances. <i>Blood</i> , 2001, 97, 1845-1853.	0.6	75
245	Prognostic Value of Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ( <sup>18</sup> F)FDG) After First-Line Chemotherapy in Non-Hodgkin's Lymphoma: Is <sup>18</sup> F)FDG-PET a Valid Alternative to Conventional Diagnostic Methods?. <i>Journal of Clinical Oncology</i> , 2001, 19, 414-419.	0.8	455
246	Autoimmune haemolytic anaemia triggered by Bartonella henselae infection: a case report. <i>British Journal of Haematology</i> , 2001, 115, 924-925.	1.2	27
247	Can positron emission tomography with [18 F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?. <i>British Journal of Haematology</i> , 2001, 115, 272-278.	1.2	159
248	NF- $\kappa$ B is involved in the regulation of CD154 (CD40 ligand) expression in primary human T cells. <i>Clinical and Experimental Immunology</i> , 2001, 125, 229-236.	1.1	36
249	Catheter-related bacteremia due to Ewingella americana. <i>Clinical Microbiology and Infection</i> , 2001, 7, 103-104.	2.8	17
250	Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. <i>Nature Genetics</i> , 2001, 27, 313-317.	9.4	401
251	Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation. <i>Immunology</i> , 1999, 98, 413-421.	2.0	77
252	CD57 <sup>+</sup> /CD28 <sup>+</sup> T cells in untreated hemato-oncological patients are expanded and display a Th1-type cytokine secretion profile, ex vivo cytolytic activity and enhanced tendency to apoptosis. <i>Leukemia</i> , 1998, 12, 1573-1582.	3.3	57



#	ARTICLE	IF	CITATIONS
253	Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors: Evidence for systemic activation of the T cell compartment. <i>Leukemia Research</i> , 1998, 22, 175-184.	0.4	64
254	Lymphocyte profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: flow-cytometric characterization and analysis in a two-dimensional correlation biplot. <i>Annals of Hematology</i> , 1998, 76, 249-256.	0.8	11
255	Patients with high-risk myelodysplastic syndrome can have polyclonal or clonal haemopoiesis in complete haematological remission. <i>British Journal of Haematology</i> , 1998, 102, 486-494.	1.2	38
256	Human CTLA-4 is expressed in situ on T lymphocytes in germinal centers, in cutaneous graft-versus-host disease, and in Hodgkin's disease. <i>American Journal of Pathology</i> , 1998, 152, 963-73.	1.9	18
257	A single course of remission reinduction chemotherapy for acute myelogenous leukemia relapsing after allogeneic bone marrow transplantation is complicated by graft-versus-host disease and followed by sustained complete remission. <i>Leukemia</i> , 1997, 11, 1775-1778.	3.3	6
258	Multivariate reconstruction of lymphocyte profiles in a two-dimensional graphical model as a tool for the investigation of lymphocyte subset distribution in health and disease. , 1997, 28, 220-227.		6
259	Successful control of refractory and life-threatening autoimmune hemolytic anemia with intravenous immunoglobulins in a man with the primary antiphospholipid syndrome. <i>Annals of Hematology</i> , 1996, 73, 253-256.	0.8	10
260	Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1996, 92, 351-359.	1.2	53
261	CD80, CD86 and CD40 Provide Accessory Signals in a Multiple-Step T-Cell Activation Model. <i>Immunological Reviews</i> , 1996, 153, 47-83.	2.8	219
262	Comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after single-dose cyclophosphamide combined with rhGM-CSF or rhG-CSF. <i>British Journal of Haematology</i> , 1995, 90, 384-392.	1.2	31
263	An update on peripheral blood progenitor cell transplantation. <i>Annals of Hematology</i> , 1995, 71, 29-33.	0.8	11
264	Graft-versus-leukemia and graft-versus-lymphoma effects of allogeneic bone marrow transplantation and of allogeneic donor leukocyte transfusions. <i>Annals of Hematology</i> , 1995, 71, 209-217.	0.8	8
265	Therapy-related acute myeloid leukemia with t(8;16)(p11;p13) following anthracycline-based therapy for nonmetastatic osteosarcoma. <i>Cancer Genetics and Cytogenetics</i> , 1995, 82, 103-105.	1.0	5
266	Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. <i>Blood</i> , 1995, 86, 3660-3667.	0.6	71
267	CD80 (B7-1) and CD86 (B7-2): Potential targets for immunotherapy?. <i>Research in Immunology</i> , 1995, 146, 183-196.	0.9	16
268	The CD28 and CTLA-4 Receptor Family (Part 1 of 2). <i>Chemical Immunology and Allergy</i> , 1994, 59, 62-76.	1.7	12
269	Ligation of B7 with CD28/CTLA-4 on T cells results in CD40 ligand expression, interleukin-4 secretion and efficient help for antibody production by B cells. <i>European Journal of Immunology</i> , 1993, 23, 3120-3125.	1.6	147
270	In situ expression of B7/BB1 on antigenpresenting cells and activated B cells: an immunohistochemical study. <i>International Immunology</i> , 1993, 5, 317-321.	1.8	63

#	ARTICLE	IF	CITATIONS
271	The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines. <i>Blood</i> , 1993, 82, 2845-2852.	0.6	73
272	The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines. <i>Blood</i> , 1993, 82, 2845-2852.	0.6	0
273	Ligation of the CD5 or CD28 molecules on resting human T cells induces expression of the early activation antigen CD69 by a calcium- and tyrosine kinase-dependent mechanism. <i>Immunology</i> , 1993, 78, 210-7.	2.0	31
274	Status report of the Leuven isotope separator on-line (LISOL). <i>Nuclear Instruments &amp; Methods in Physics Research B</i> , 1992, 70, 50-55.	0.6	22
275	Immobilized anti-CD5 together with prolonged activation of protein kinase C induce interleukin 2-dependent T cell growth: evidence for signal transduction through CD5. <i>European Journal of Immunology</i> , 1991, 21, 251-259.	1.6	41
276	Crosslinking of the CD5 antigen on human T cells induces functional IL2 receptors. <i>Cellular Immunology</i> , 1990, 131, 109-119.	1.4	13
277	Flow cytometric measurement of cytoplasmic free calcium in human peripheral blood T lymphocytes with fluo-3, a new fluorescent calcium indicator. <i>Journal of Immunological Methods</i> , 1990, 127, 197-205.	0.6	176
278	Cat-scratch disease with reversible encephalopathy. <i>European Journal of Pediatrics</i> , 1989, 149, 24-25.	1.3	5
279	Characterization of ATP-driven calcium uptake in renal basal-lateral and renal endoplasmic reticulum membrane vesicles. <i>Cell Calcium</i> , 1985, 6, 413-429.	1.1	18
280	Genetics of Chronic Lymphocytic Leukemia: Practical Aspects and Prognostic Significance. , 0, , .		2